The global challenge of diabetes necessitates continuous innovation in treatment strategies. Harmine HCl (CAS 343-27-1) represents a significant breakthrough in this area, particularly concerning pancreatic beta cell regeneration. Its unique ability to induce the proliferation of pancreatic alpha and beta cells in adult humans is a groundbreaking discovery, offering new avenues for restoring insulin production in diabetic patients. This makes Harmine an invaluable compound for diabetes and metabolic disorder research chemicals.


Harmine functions as a competitive inhibitor of ATP binding to the kinase pocket of DYRK1A. This inhibition is crucial because DYRK1A plays a role in negatively regulating beta cell proliferation. By inhibiting DYRK1A, Harmine essentially 'unlocks' the regenerative capacity of these vital cells. Studies have shown that Harmine treatment can significantly accelerate the regeneration of beta cell mass, even reaching near-normal values in animal models of partial pancreatectomy. Understanding the Harmine DYRK1A inhibitor price is key for institutions planning large-scale research.


For researchers focused on developing therapies for Type 1 and Type 2 diabetes, Harmine HCl provides a compelling lead compound. Its potential to increase islet mass and improve glycemic control in preclinical models underscores its therapeutic promise. The demand for high-purity, pharmaceutical-grade Harmine HCl for beta cell proliferation studies is growing rapidly. NINGBO INNO PHARMCHEM CO.,LTD. is a leading pharmaceutical grade Harmine HCl manufacturer, committed to supplying the consistent quality needed for such sensitive biological investigations.


The ability to induce beta cell growth in a controlled manner is a major step forward in diabetes treatment, moving beyond current insulin replacement therapies to address the root cause of the disease. NINGBO INNO PHARMCHEM CO.,LTD. offers competitive pricing and ensures the highest purity for your Harmine hydrochloride for beta cell proliferation research. Our dedication supports your efforts to uncover new therapeutic pathways and bring effective solutions to patients worldwide, reinforcing Harmine HCl's role as a vital component in advanced metabolic health research.